Cross-Sector entity
Talcum Powder Products is most often covered alongside Chris Seeger, which appears in 3 of these 3 stories. The clearest coverage concentration is corporate-law: 1 of 3 stories, with the rest divided among 2 other categories. Talcum Powder Products appears in 3 tracked Cross-Sector stories from July 28, 2026.
3 verified stories tracked
Last mentioned: Jul 28, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Talcum Powder Products is most often covered alongside Chris Seeger, which appears in 3 of these 3 stories. The clearest coverage concentration is corporate-law: 1 of 3 stories, with the rest divided among 2 other categories. Talcum Powder Products appears in 3 tracked Cross-Sector stories from July 28, 2026. The tracked stories average 3 original sources each.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Talcum Powder Products. Shared-story counts are live from our verified record — not editorial picks.
$5.5B Settlement Announced
J&J proposes a global settlement to resolve around 76,000 pending ovarian cancer talc lawsuits, contingent on 95% claimant approval.
Bankruptcy Dismissal
Courts dismiss the LTL Management bankruptcy, ruling it was not filed in good faith, sending talc cases back to trial courts.
LTL Management Files for Bankruptcy
J&J employs the 'Texas two-step' strategy, shifting talc liabilities to subsidiary LTL Management, which files for Chapter 11.
J&J Stops Talc Baby Powder Sales in the U.S.
Facing mounting lawsuits, J&J discontinues talc-based baby powder in the U.S. and switches to a cornstarch-based product.
The $5.5B proposal to resolve 76,000 ovarian cancer talc lawsuits represents a strategic retreat for J&J, contingent on 95% claimant approval and following failed bankruptcy attempts.
The settlement highlights decades of health concerns over talc's link to ovarian cancer, prompting J&J to switch to cornstarch and underscoring ongoing consumer trust issues.
The settlement removes a major litigation distraction, allowing Johnson & Johnson to redirect resources toward its core pharmaceutical and medtech segments, which generate $85B in annual revenue.
Source: 1190talkradio.iheart.com · manilatimes.net
